Fig. 3: Impact of tumor genomics on disease outcomes. | Nature Communications

Fig. 3: Impact of tumor genomics on disease outcomes.

From: Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC

Fig. 3

a Oncoprint of study population. b Local-regional control rate at 24-months, c progression-free, and d overall survival to concurrent CRT and durvalumab by TP53 and DNA-damage repair (DDR) mutation status in NSCLC. Outcomes by KRAS, STK11, and KEAP1 mutation status in nonsquamous NSCLC. In addition, outcomes by TP53, STK11, and KEAP1 mutation status in KRASWT and KRASMUT nonsquamous NSCLC are also shown. Data are presented as the hazard ratio (HR) with error bars showing 95% confidence interval. HRs were calculated with Cox proportional hazard regression for (c)and (d). P-values are according to log-rank test for (b), (c), and (d). CRT chemoradiation, HR hazard ratio, CI confidence interval, MSKCC Memorial Sloan Kettering Cancer Center, DFCI Dana-Farber Cancer Institute. Source data are provided as a Source Data file.

Back to article page